[Chemotherapy of head and neck carcinomas. Association of adriamycine, vincristine and methotrexate (author's transl)].
Phase II of a study of chemotherapy using adriamycine, vincristine and methotrexate is reported. Forty-six patients with carcinoma of the head and neck were treated; thirty-eight of these results can be evaluated. The degree of objective response is mainly influenced by the site of the tumour. It can vary from 8/23 to twice that figure 16/23 depending on whether the tumour is located in the territory which was previously irradiated. The mean duration of response is short, 2,5 months. The treatment seems to be quite toxic.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D014750:Vincristine; D004317:Doxorubicin; D008727:Methotrexate
Chimiothérapie des carcinomes épidermoöides des voies aérodigestives supérieures. Association d'adriamycine, vincristine et méthotrexate.